Using a novel CRISPR gene editing approach the team screened 500 genes associated with head and neck cancer for their ability to trigger cancer in mice. Almost all the genes they identified as promoting the cancer were not independent from each other, but influenced the same growth regulatory pathway – the NOTCH pathway.
In 2015, Daniel Schramek of the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital in Toronto was awarded a CDA to work on “Dissecting oncogenic networks by functional genomics using multiplexed genome editing in vivo.”
New-born mouse transduced with CRISPR/Cas9-Cre construct showing emergence of thousands of independent, fluorescently-tagged clones.
You can read more on this recent breakthrough, which was published in Science, in a press release by Sinai Health.